The most important challenge facing Biopharmaceutical companies today is to reduce development time consistent with others to get products to market faster. It is estimated that companies can achieve sales of $135 million by introducing a product 3 months earlier. This has been one of the compelling reasons why the iCE280 IEF analyzer has rapidly become the platform technology of choice for charge based methods.

We are committed to support our technology wherever our clients transfer methods, whether it is internally to other departments or divisions or externally to partners, CMOs and CROs. The receivers of these transfers may be located in the host country or in a different country. For information on service and sales in North America or internationally, please click on "Our Contacts" for North America, Europe and Asia (China, India and Japan).